---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055087"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:52:10.494414+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aptevo Q1 net loss $6.8M; breast cancer patient stays on ALG.APV-527 >11 months

## Summary
- Net loss $6.8M ($9.95 per share) vs net income $2.8M ($17.38 per share) in Q1 2023.
- Cash $10.3M at March 31, 2024; pro forma $14.3M after April equity raise.
- Heavily pretreated breast cancer patient in ALG.APV-527 Phase 1 achieved stable disease, remains on therapy >11 months, safely transitioned to higher dose.
- APVO436 Phase 1b/2 frontline AML dose optimization trial initiation expected Q2 2024; partnered with Prometrika.
- R&D expenses down $0.4M to $3.8M; G&A down $0.4M to $3.2M.

## SEC filing metadata
- accession: 0000950170-24-055087
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/0000950170-24-055087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/apvo-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055087
- JSON: https://secwatch.observer/filing/0000950170-24-055087.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055087.txt

## Key facts
- Earnings Releases
  Aptevo Therapeutics Inc. reported the quarter ended March 31, 2024 results: net income a net loss of $6.8 million or $9.95 per share, EPS $9.95 per share.
  - Period: the quarter ended March 31, 2024
  - Net income: a net loss of $6.8 million or $9.95 per share
  - EPS: $9.95 per share
  - Result: reported results
  source text: Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/0000950170-24-055087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.